The board of directors of Deprenyl Research Ltd. recommendeda 2-for-1 stock split. The recommendation will be presented toshareholders of the Toronto, Ontario, company at the May 19annual meeting. The company has 16.4 million sharesoutstanding before the split. Deprenyl (NASDAQ:DEPLF), whichis developing Eldepryl deprenyl to treat Parkinson's disease,last August declared a 1-for-1 stock dividend. The sharesclosed at $19.50, up 25 cents.
(c) 1997 American Health Consultants. All rights reserved.